A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry.
biomarker
cerebrospinal fluid
diagnosis
glioma
multiple sclerosis
primary central nervous system lymphomas
proteomics
secondary central nervous system lymphomas
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2020
29 Jun 2020
Historique:
received:
25
05
2020
revised:
25
06
2020
accepted:
26
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Primary central nervous system lymphomas (PCNSL) account for approximately 2% to 3% of all primary brain tumors. Until now, neuropathological tumor tissue analysis, most frequently gained by stereotactic biopsy, is still the diagnostic gold standard. Here, we rigorously analyzed two independent patient cohorts comprising the clinical entities PCNSL (
Identifiants
pubmed: 32610669
pii: cancers12071732
doi: 10.3390/cancers12071732
pmc: PMC7407338
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : STU 486/5-1
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHL 268/4-1
Organisme : Wilhelm Sander-Stiftung
ID : 2011.092.2.
Références
Nat Rev Neurol. 2013 Jun;9(6):317-27
pubmed: 23670107
Am J Clin Pathol. 1998 Nov;110(5):607-12
pubmed: 9802345
PLoS One. 2018 Aug 16;13(8):e0202530
pubmed: 30114292
Neurol Res. 2000 Jul;22(5):434-42
pubmed: 10935213
Regul Pept. 2003 Mar 28;111(1-3):169-78
pubmed: 12609765
Leukemia. 2011 Dec;25(12):1797-807
pubmed: 21818113
Expert Rev Anticancer Ther. 2019 Oct;19(10):909-915
pubmed: 31594423
Int J Lab Hematol. 2008 Jun;30(3):230-9
pubmed: 18479302
Blood. 1996 Mar 1;87(5):1985-9
pubmed: 8634448
Neuro Oncol. 2012 Mar;14(3):368-80
pubmed: 22156547
Curr Probl Diagn Radiol. 2017 Mar - Apr;46(2):136-145
pubmed: 27475832
Metabolism. 2012 Jul;61(7):906-21
pubmed: 22304839
Am J Hematol. 2013 Dec;88(12):997-1000
pubmed: 23873804
Mol Cell Proteomics. 2019 Sep;18(9):1836-1850
pubmed: 31289117
Stat Med. 2013 May 20;32(11):1893-903
pubmed: 22972679
Oncotarget. 2017 Nov 24;8(66):110118-110132
pubmed: 29299134
Mult Scler. 2020 Apr;26(5):582-590
pubmed: 31965889
J Clin Oncol. 2006 Mar 10;24(8):1281-8
pubmed: 16525183
J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4
pubmed: 19332721
J Clin Invest. 2006 Oct;116(10):2817-26
pubmed: 17016562
J Clin Oncol. 2008 Jan 1;26(1):96-105
pubmed: 18056677
Cancer Lett. 1998 Oct 23;132(1-2):181-6
pubmed: 10397472
Blood. 2013 Jun 6;121(23):4740-8
pubmed: 23570798
Lancet Oncol. 2001 Jun;2(6):354-65
pubmed: 11905752
Clin Cancer Res. 2009 Oct 1;15(19):5968-73
pubmed: 19773382
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82
pubmed: 16609006
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13519-13524
pubmed: 29203663